Sonia Brugnara
Overview
Explore the profile of Sonia Brugnara including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
111
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rubatto M, Fava P, Stanganelli I, Ribero S, Pigozzo J, Di Giacomo A, et al.
Eur J Cancer
. 2023 Apr;
187:25-35.
PMID: 37099946
Background: Immunotherapy has improved the survival of patients with stage IV melanoma. In responders, clinical benefits may be long-lasting and persist even after treatment discontinuation. The optimal duration of anti-PD1...
2.
Brugnara S, Sicher M, Bonandini E, Barbareschi M, Girardelli C, Caffo O
Drugs Context
. 2020 Mar;
8:212582.
PMID: 32158480
Systemic treatment for metastatic melanoma has advanced dramatically in recent years with an impressive increase in the rate of overall survival. The two main different strategies are targeted therapies (i.e....
3.
Pellegrini C, Botta F, Massi D, Martorelli C, Facchetti F, Gandini S, et al.
Lancet Child Adolesc Health
. 2019 Mar;
3(5):332-342.
PMID: 30872112
Background: Germline variants in the melanocortin 1 receptor gene (MC1R) might increase the risk of childhood and adolescent melanoma, but a clear conclusion is challenging because of the low number...
4.
Brugnara S, Sicher M, Bonandini E, Donner D, Chierichetti F, Barbareschi M, et al.
Drugs Context
. 2018 Feb;
7:212515.
PMID: 29483930
Here, we report the case of a patient, diagnosed with -mutated metastatic malignant melanoma M1a, who achieved a complete metabolic response after 7 months of treatment with the combination of...
5.
Dipasquale M, Murgia V, Veccia A, Brugnara S, Caldara A, Ferro A, et al.
Anticancer Drugs
. 2017 Mar;
28(6):654-659.
PMID: 28252532
To assess the activity of weekly paclitaxel (wPCT) in pretreated patients with advanced non-small-cell lung cancer (aNSCLC). In 2005, we included wPCT 80 mg/m for 6 consecutive weeks, followed by...
6.
Marabese M, Caiola E, Garassino M, Rastelli G, Settanni G, Brugnara S, et al.
J Thorac Oncol
. 2016 Apr;
11(7):1170-5.
PMID: 27058911
A new somatic mutation in the coding region of Kirsten rat sarcoma viral oncogene homolog gene (KRAS), G48A, has been identified in a patient with non-small cell lung cancer (NSCLC)....
7.
Caffo O, Pappagallo G, Brugnara S, Caldara A, di Pasquale M, Ferro A, et al.
Urology
. 2012 Mar;
79(3):644-9.
PMID: 22386418
Objective: To describe the feasibility and efficacy of multiple sequential rechallenges and analyze the predictive factors that may aid in selecting patients who are more likely to respond. Several studies...
8.
Aldovini D, Demichelis F, Doglioni C, Di Vizio D, Galligioni E, Brugnara S, et al.
Int J Cancer
. 2006 Jun;
119(8):1920-6.
PMID: 16804906
Currently available clinico-pathologic criteria provide an imperfect assessment of outcome for patients with advanced epithelial ovarian cancer (EOC). Identification of prognostic factors related to tumor biology might improve this assessment....
9.
Ridolfi R, Chiarion-Sileni V, Guida M, Romanini A, Labianca R, Freschi A, et al.
J Clin Oncol
. 2002 Mar;
20(6):1600-7.
PMID: 11896110
Purpose: Phase II and III studies have shown that the addition of interleukin-2 (IL-2) and interferon alpha-2b (IFN alpha-2b) in multiagent chemotherapy (CT) for advanced melanoma increases overall response (OR),...